Special Issue "Epidemiology, Prognosis and Antimicrobial Treatment of Extensively Antibiotic-Resistant Bacterial Infections"
Deadline for manuscript submissions: 30 March 2022.
2. School of Health and Related Research, Section of Public Health, University of Sheffield, Sheffield, UK
Interests: medical statistics; epidemiological methods; healthcare epidemiology; infection control; antimicrobial resistance; surveillance; public health
Special Issues and Collections in MDPI journals
Interests: infectious diseases; infection control; antimicrobial resistance; antibiotic therapy; antibiotic stewardship; clinical epidemiology
Infections caused by extensively drug-resistant (XDR) bacteria, including pandrug-resistant (PDR) bacteria, are increasingly being reported in several countries worldwide. These organisms are typically isolated from patients in intensive care units, but intra- and inter-hospital dissemination, and even international spread, may be substantial. Timely research on the population burden (prevalence and incidence), time trends, geographical spread, and dissemination in long-term care facilities and community settings of XDR and PDR bacteria is of crucial importance. Prognostic studies, including diagnostic prediction models, for the emergence and spread of resistance to newer antibiotics (including cefiderocol, eravacycline, and plazomicin) and their impact on patient outcomes and on the effectiveness of antibiotic therapy (especially with newer antibiotics and synergistic combinations) related to infections caused by XDR and PDR bacteria are of special interest.
Antimicrobial resistance phenotypes for which timely research is much needed include (but are not limited to):
- Acinetobacter spp susceptible only to one or more: polymyxins, tigecycline or minocycline or eravacycline, cefiderocol;
- Metallo-beta-lactamase producing Pseudomonas aeruginosa (i.e., co-resistant to carbapenems, ceftazidime/avibactam, ceftolozane/tazobactam, and imipenem/relebactam);
- Aztreonam/avibactam-resistant Enterobacterales;
- XDR Stenotrophomonas maltophilia;
- Cefiderocol-resistant XDR/PDR Gram-negative bacteria.
This Special Issue welcomes submissions of clinical and epidemiological original research, clinical prediction models, systematic reviews, meta-analyses, and narrative literature reviews on the current epidemiology, diagnosis, prognosis, and treatment options for pathogens exhibiting extensive resistance phenotypes.
Prof. Evangelos I. Kritsotakis
Dr. Stamatis Karakonstantis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antibiotic resistance
- extensive antimicrobial resistance
- clinical epidemiology
- antibiotic therapy